NPB5005-V283 / Neomics Pharmaceuticals - LARVOL DELTA

Phase I study of NPB5005-V283 in patients with relapsed/refractory multiple myeloma (ASH 2025) - "Patients are administered infusion of NPB5005-V283 following lymphodepletion byfludarabine 30 mg/m2 and cyclophosphamide 300 mg/m2 daily for 3 days. As of July 31, 2025, 4 patients of Han ethnicity were enrolled. 2 male sex (50%), median age was62 years (range 50–73), median time from MM diagnosis was 4.2 years (range 3.5-5), received median 4.5prior lines of treatment (range 3-6), 2 (50%) patients had high-risk cytogenetics, 1(25%) hadextramedullary disease, 1(25%) had high tumor burden of 81% BMPCs,Products had been successfully manufactured for all patients. Patients received bridging therapybetween apheresis and infusion."

Clinical • P1 data • Hematological Malignancies • Infectious Disease • Multiple Myeloma • CD8 • ICOS